Imunon Inc

Imunon, Inc. management highlighted continued validation of its TheraPlas platform through final Phase 2 survival data and preliminary minimal residual disease study findings during its second quarter 2026 earnings call. The final OVATION II study results showed a median overall survival of 45.1 months in the treatment arm versus 30.4 months in the control group, a 14.7-month improvement, while patients receiving PARP inhibitor maintenance therapy saw a 24.2-month increase to 65.6 months compared with 41.4 months in the control arm. Enrollment in the pivotal Phase 3 OVATION III trial is running at 0.5 patients per site per month, exceeding the internal assumption of 0.3 and the historical industry rate of 0.2, with 35% of planned sites active or in activation and management expecting to complete enrollment by the first half of 2029. The company reported a net loss of $2.8 million, or $0.54 per share, and cash and cash equivalents of $6.9 million as of June 30, 2026, supported by a $10 million financing in June designed to minimize shareholder dilution. Leadership also noted plans to submit final overall survival data to a major medical conference in early 2027 and to host an R&D Day on September 23, 2026.

IMUNON announced positive preliminary data from its ongoing Phase 2 minimal residual disease trial of IMNN-001 in newly diagnosed advanced ovarian cancer. Among the first 18 of 30 patients to reach the primary assessment point of second-look laparoscopy, those treated with IMNN-001 plus standard chemotherapy and bevacizumab achieved an 87.5% circulating tumor DNA clearance rate versus 62.5% in the placebo arm, and 100% showed no evidence of disease compared to 56% in the placebo group. The treatment continued to demonstrate a favorable safety profile with no cytokine release syndrome or serious immune-related adverse events. IMNN-001 is an IL-12 DNA-based immunotherapy, and the company is also evaluating it in the pivotal Phase 3 OVATION 3 trial.

This week brought a mix of FDA and EU approvals, layoffs, acquisitions, and clinical trial updates across the biotech sector. Ionis Pharmaceuticals secured FDA approval for TRYNGOLZA as an adjunct therapy for severe hypertriglyceridemia, while Merck received European Commission approval for Keytruda in combination with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. Gilead's Trodelvy was cleared by the FDA for first-line metastatic triple-negative breast cancer, and Pfizer's IBRANCE won expanded approval for HR+/HER2+ metastatic breast cancer. Natera gained Japanese approval for its Signatera MRD test in colorectal cancer, and AbbVie's MAVIRET was approved in the EU for both acute and chronic Hepatitis C. Achieve Life Sciences received an FDA Complete Response Letter for its Cytisinicline NDA due to manufacturing deficiencies, though no efficacy or safety issues were raised. ADC Therapeutics announced a 17% workforce reduction as part of a strategic reorganization to focus on its ZYNLONTA lymphoma franchise. In dealmaking, Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, representing an enterprise value of $11.3 billion, while Ionis inked a licensing deal with Recordati for Zilganersen, an investigational therapy for Alexander disease. Passage Bio and Remix Therapeutics entered an all-stock merger agreement, and Boundless Bio and Serapha Bio also announced an all-stock merger. On the clinical front, IMUNON's Phase 3 OVATION 3 trial passed a safety review, Takeda's Zasocitinib showed superiority over Deucravacitinib in a Phase 3 psoriasis study, and Eledon reported positive long-term kidney transplant data for Tegoprubart. However, Pfizer's Sigvotatug vedotin missed its primary overall survival endpoint in a Phase 3 non-small cell lung cancer study, and MapLight's ML-004 failed to meet its primary endpoint in autism spectrum disorder, though it showed an irritability signal in adolescents. Definium Therapeutics reported positive Phase 3 results for DT120 ODT in major depressive disorder.